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Abstract
Background: Melanoma metastasis status is highly associated with the overall survival of patients; yet, little is known about
proteomic changes during melanoma tumor progression. To better understand the changes in protein expression involved
in melanoma progression and metastasis, and to identify potential biomarkers, we conducted a global quantitative
proteomic analysis on archival metastatic and primary melanomas.
Methodology and Findings: A total of 16 metastatic and 8 primary cutaneous melanomas were assessed. Proteins were
extracted from laser captured microdissected formalin fixed paraffin-embedded archival tissues by liquefying tissue cells.
These preparations were analyzed by a LC/MS-based label-free protein quantification method. More than 1500 proteins
were identified in the tissue lysates with a peptide ID confidence level of .75%. This approach identified 120 significant
changes in protein levels. These proteins were identified from multiple peptides with high confidence identification and
were expressed at significantly different levels in metastases as compared with primary melanomas (q-Value,0.05).
Conclusions and Significance: The differentially expressed proteins were classified by biological process or mapped into
biological system networks, and several proteins were implicated by these analyses as cancer- or metastasis-related. These
proteins represent potential biomarkers for tumor progression. The study successfully identified proteins that are
differentially expressed in formalin fixed paraffin-embedded specimens of metastatic and primary melanoma.
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Introduction
The potential for primary melanomas to metastasize increases
with the depth of invasion. The diagnosis of distant metastatic
cutaneous melanoma is usually associated with poor prognosis.
Currently, no single protein marker reliably predicts disease
outcome in cutaneous melanoma. Understanding the mechanisms
of metastasis and identifying proteomic biomarkers associated with
melanoma progression and metastasis may aid in developing
treatment strategies. In recent years, many studies have investi-
gated gene expression signatures based on mRNA levels in
melanomas [1,2,3]. However, changes at the mRNA level may not
always directly correlate to changes at the protein level;
translational and post-translational alterations also affect tumor
progression and metastasis. Proteomics screening tools may
identify relevant and significant changes in protein expression in
relation to early and advance stage cancers.
Two-dimensional polyacrylamide gel electrophoresis (2D-
PAGE) coupled with tandem mass spectrometry (MS/MS) has
been the principal tool for proteomic analysis of melanoma tissue
[4,5], but little data has been reported about the proteomic
expression profiles of primary versus metastatic melanoma tissues.
The ion intensity-based, label-free quantitative proteomics (LFQP)
approach has gained popularity as mass spectrometer performance
has significantly improved [6,7,8]. LFQP provides a powerful tool
to resolve and identify thousands of proteins from a complex
biological sample. Proteins are digested with a protease, and the
peptide mixture is analyzed by liquid chromatography-mass
spectrometry (LC/MS) and liquid chromatography with tandem
mass spectrometry (LC/MS/MS); the relative protein abundance
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The LFQP approach is rapid and more sensitive than many other
proteomic methods, and it increases the protein dynamic range 3-
to 4-fold as compared to 2D-PAGE. This method can also be
automated for large-scale proteome analysis.
To identify the mechanisms and proteomic biomarkers of
melanoma metastasis, we used an LC/MS-based label-free protein
quantification method to profile the global protein expression of
microdissected primary and metastatic melanoma formalin fixed
paraffin-embedded (FFPE) archival tissues. Proteins were extract-
ed using reagents and protocols that yield a product suitable for
MS analysis [9,10]. The overall objective was to determine if
proteomic profiling differences could be identified in FFPE tissue
specimens of primary and metastatic cutaneous melanomas.
Methods
Tissue Processing
Formalin-fixed tissue blocks from 8 primary (five AJCC stage II
and three AJCC stage III) and 16 metastatic melanomas (5 AJCC
stage III lymph nodes and AJCC stage IV: 4 lung, 4 brain, 1 colon,
1 adrenal gland, and 1 extremity) were chosen for analysis. All
cutaneous melanomas were identified by standard histopathology
techniques. Five mm thick tissue sections were stained with
hematoxylin and eosin to identify an 8-mm
2 area containing
defined melanoma cells for dissection. For tissue isolation and
preparation of analyzable protein, the manufacturer’s recommen-
dations were followed (Expression Pathology, Inc., Gaithersburg,
MD). In brief, a single 10-mm tissue section was cut from each
tissue block, treated with xylene to remove paraffin, rehydrated
through a series of graded ethanol solutions and distilled water,
and stained with hematoxylin. An area 8 mm
2 in size, corre-
sponding to approximately 30,000 cells from the relevant region,
was procured by microdissection for processing. Informed patient
consents for all studies were approved by the human subjects IRB
of Saint John’s Health Center and JWCI. All of the consents are
written and verbally explained to the patients. Patients’ specimens
were de-identified and run in a double-blinded manner.
Sample Preparation
Collected microdissected tissue was processed with the Liquid
TissueH MS Protein Prep Kit (Expression Pathology, Inc.). Briefly,
the tissue was suspended in 20 ml of Liquid Tissue Buffer,
incubated at 95uC for 90 min, and then cooled on ice for 2 min.
Trypsin (1 mg) was added, and then the tissue was incubated at
37uC overnight. The sample was then heated for 5 min at 95uCt o
inactivate the trypsin. After the total amount of extracted protein
was measured by a micro BCA (bicinchoninic acid) protein assay
(PIERCE, Rockford, IL), DTT was added for a final concentra-
tion of 10 mM. The sample was stored at 220uC until LC/MS/
MS analysis.
LC/MS/MS Analysis
Trypsin-digested samples (1 mg each) were injected onto an
Agilent 1100 nano-HPLC system (Agilent Technologies, Inc.,
Santa Clara, CA) with a C18 capillary column in random order.
Peptides were eluted with a linear gradient from 5 to 45%
acetonitrile developed over 120 min at a flow rate of 500 nL/min,
and effluent was electro-sprayed into the LTQ mass spectrometer
(Thermo Fisher Scientific Inc., Waltham, MA). Data was collected
in the ‘‘Triple-Play’’ (MS scan, Zoom scan, and MS/MS scan)
mode. The acquired data were filtered and analyzed by a
proprietary algorithm [11]. Database searches against the
International Protein Index (IPI) human database (European
Bioinformatics Institute, 2005) and the Non-Redundant-homo
sapiens database (National Center for Biotechnology Information,
2005) were carried out using both the X!Tandem [12] and
SEQUEST [13] algorithms. Protein quantification was carried out
using the same algorithm described above [11]. Briefly, when the
raw files were acquired from the LTQ mass spectrometer, all
extracted ion chromatograms (XICs) were aligned by retention
time. To be used in the protein quantification procedure, each
aligned peak must have a matched precursor ion, charge state,
fragment ions (MS/MS data) and retention time (within a one-
minute window). After alignment, the area-under-the-curve (AUC)
for each individually aligned peak from each sample was
measured, normalized, and compared for relative abundance as
previously described [11].
After obtaining the list of proteins that were differentially
expressed in primary and metastatic samples from the LC/MS
quantitative analysis, a corresponding gene list was created and
input for bioinformatics analysis.
Biostatistics Analysis
Since the data has multiple sources of random variation, such as
biological samples and replicates, a Linear Mixed Model (a
generalization of an ANOVA, Analysis of Variance) was used for
biostatistics analysis in this study. This model, especially when
applied to complex experimental designs, cannot be handled by
introductory methods such as t-tests. Also, the exact scale of the
protein expression used in the model can make a difference in the
sensitivity. In general, there is usually a large technical variation
introduced by the act of ‘measurement’ in many ‘omics’ studies.
Randomization of measurement order and normalization of the
data will eliminate the technical bias. We used a statistically based
quantile normalization method for data normalization [14].
Because ‘omics’ measures of expression are usually on an arbitrary
scale, we chose to evaluate ratios or their equivalent differences on
a log scale [15]. Log base 2 was chosen because a unit difference
on the log scale is equivalent to a two-fold change.
A byproduct of the Linear Mixed Model is a p-Value or
measure of significance for an observed change in protein
expression (signal). The p-Value estimates the proportion of times
a change that large will be observed if in fact there is no real
change (the False Positive Rate). All the p-Values were then
transformed into q-Values that estimate the False Discovery Rate
(FDR) [16].
For each protein a separate analysis of variance (ANOVA)
model is fit:
Log2 Intensity ðÞ ~
Group Effect
Fixed ðÞ
zSample Effect
Random ðÞ
zReplicate Effect
Random ðÞ
Log2(Intensity) is the protein intensity based on the weighted
average of the quantile normalized log base 2 peptide intensities
with the same protein identification. Group Effect refers to the fixed
effects (not random) caused by the experimental conditions or
treatments that are being compared. Sample Effect (nested within
group) refers to the random effects from individual biological
samples. It also includes the random effects from the individual
sample preparations. Replicate Effect (nested within sample) refers to
the random effects from replicate injections from the same sample
preparation.
When an ANOVA model has two or more random effects
(sample and replicate in this data) and at least one fixed effect
(group in this data) it is referred to as a Mixed Model. For each
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software (version 9) (SAS Institute Inc., Cary, NC). The REML
method was used as a fit mechanism and degrees of freedom were
computed using the Satterthwaite method. The RANDOM
statement was used to model the covariance with the NOBOUND
parameter option in the PROC statement.
Immunohistochemistry Analysis
Selective protein expressions were assessed by immunohisto-
chemistry (IHC) on FFPE melanoma tissues. Five-mm sections
were cut from FFPE archival tissue blocks and incubated overnight
at 50uC for IHC preparation. The sections were then depar-
affinized in xylene and rehydrated in ethanol. All IHC staining
was conducted with the CSA II kit (CSA II, Biotin-Free Tyramide
Signal Amplication System; Dakocytomation) as described previ-
ously [17]. To perform heat-induced antigen retrieval, sections
were placed into 10 mM citrate buffer (pH 6.0) and heated to
100uC for 20 min. Endogenous peroxidase function was quenched
with peroxidase blocking solution. Nonspecific protein binding
sites were blocked with serum-free protein blocking solution.
Sections were incubated with anti-STAT1 mAb (BD Transduc-
tion, San Jose, CA) at 1:400 dilution in PBS for 30 min at room
temperature, or anti-MIF mAb (Abcam, Cambridge, MA) at 1:100
dilution in PBS, anti-pyruvate kinase (PKM1/M2) (Abcam) at 1:50
dilution in antibody diluent (Dakocytomation) with 1% BSA, or
prediluted anti-HSP90a (Hsp86 antibody, Abcam) overnight at
4uC. Negative control slides were incubated under the same
conditions with universal negative control-mouse antibody or
universal negative control-rabbit (Dakocytomation), respectively.
After washing, tissue sections stained with mouse monoclonal
primary antibodies were incubated for 15 min at room temper-
ature with horseradish peroxidase conjugated anti-mouse Ig
antibodies. CSA II Rabbit Link (DakoCytomation) was used for
the detection of rabbit primary antibodies. The amplification
system provided with the CSA II kit was applied as directed in the
manufacturer’s instructions. Slides were developed with DAB.
Sections were counterstained with half-strength Gill’s hematoxylin
(Fisher Scientific) for 30 sec, then dehydrated and mounted.
Sections were evaluated and photographed using a Nikon Eclipse
Ti microscope system.
Pathway Networks Analysis
The differentially expressed proteins were mapped into
biological networks by using a manually curated proprietary
database (MetaCore
TM, GeneGo, St. Joseph, MI), a pathway
analysis tool. Gene symbols of differentially expressed proteins
were uploaded into the database. For enrichment analysis, gene
IDs of the uploaded files were matched with gene IDs in functional
ontologies in MetaCore
TM [18], that included canonical pathway
maps (GeneGo maps), GeneGo cellular processes, Gene Ontology
(GO) cellular process and diseases categories. Canonical pathway
maps represent a set of about 500 signaling and metabolic maps
covering human biology. For network analysis, analyze networks
(AN), transcription regulation and direct interactions algorithms
were used. The analyze networks algorithm, a variant of the
shortest paths algorithm, uses relative enrichment and relative
saturation to generate subnetworks prioritized by their number of
canonical pathways [19].
Results
Proteomic Profiling of FFPE Melanoma Tissue
Proteins were extracted from microdissected melanoma FFPE
tissues and the global protein expression profile in metastases was
compared to that in primary tissues. MS analysis results are
summarized in Table 1. Of the 1557 proteins identified and
quantified, 555 proteins were identified with high confidence
(Priority 1). The identified proteins were found in every cell
compartment and appeared to cover a broad range of biological
functions. Of the 555 Priority 1 proteins, 120 proteins were
differentially expressed (q,0.05) in primary and metastatic
melanomas. The q-value, an adjusted p-value, was used to
estimate the False Discovery Rate (FDR) [20]. A False Discovery is
a when protein is falsely declared to be changed. The significance
threshold sets the FDR at less than 5%. The replicate median
percentage coefficient of variation (%CV) for the Priority 1
proteins was 7.6%, and the combined replicate plus sample
median %CV was 15%.
Characterization of Identified Proteins
To investigate the properties of identified proteins, the 1557
identified proteins were classified based on the cellular location or
biological process of the protein using the GO database (Figure 1).
Proteins that were not described or unspecified in the GO
database were screened out and not further assessed for this report.
The melanosome is a tissue specific organelle containing
melanin pigments. It is of interest to investigate how well the
melanosomal proteins were extracted and identified in this study,
since melanoma is associated with changes in pigmentation and
melanosome biogenesis, and melanogenesis related proteins have
been used as melanoma biomarkers [21,22,23]. Of the common
melanosomal proteins 79 out of 100 were identified using our
method. These common proteins are known as constituent and
resident proteins of the melanosome. There are six well-known
Table 1. LC/MS-based Label-free Protein Quantification Method.
Protein
Priority
Peptide ID
Confidence
Multiple
Sequences
Number of
Proteins
Number Significant
Changes
Maximum
Foldchange*
Median
%CV**
Median
%CV***
1 HIGH YES 555 120 2.8 7.6 15
2 HIGH NO 480 133 6.8 14 25.3
3 LOW YES 8 3 2 9.5 24.4
4 LOW NO 514 227 7.1 13 32.9
Overall 1557 483 7.1 11.7 22.6
*Absolute Fold Change.
**replicate.
***replicate+sample.
doi:10.1371/journal.pone.0004430.t001
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melanomas: tyrosinase, TRP1/TYRP1, TRP2/DCT, gp100/
pmel17, MART1, and GPR43/OA1. These proteins have been
shown to play either an enzymatic or structural role in melanin
synthesis [24,25,26]. Four out of six of these well-known
melanosome-specific proteins found in cutaneous melanomas
were identified in our proteomic profiling.
Differentially Expressed Proteins in Metastasis
Of the 120 differentially expressed (q,0.05) proteins in priority
1, 61 had expression levels that differed by more than 20%
between metastatic and primary melanoma (Table 2). A cut-off of
20% was selected based on a 15% median CV of the combined
replicate and sample (Table 1). Of the 61 differentially expressed
proteins, 38 were up-regulated and 23 were down-regulated.
To further interpret the likely roles of differentially-expressed
proteins involved in melanoma metastasis, we used the MetaCor-
e
TM pathway mapping tool to analyze and build the biological
networks related to these proteins. First, we investigated the
enrichment of the 61 differentially expressed proteins across two
different ontological categories using GeneGo canonical pathway
maps and GeneGo processes by calculating the hypergeometric
distribution p-value of this list with respect to each category.
Figure 2A shows the top ten GeneGo canonical pathway maps
associated with the differentially expressed proteins and Figure 2B
shows the top ten GeneGo cellular process networks. Glycolysis
and gluconeogenesis, which involve PGK1, GAPDH, GAPDHS,
PKM2, LDHA, and LDHB proteins, are suggested to have the
highest significance in the pathway maps. Translation initiation
and protein folding are the two most significant cellular process
networks. Individual mapping of up-regulated and down-regulated
proteins showed that glycolysis and gluconeogenesis were the most
up-regulated pathways, while DNA damage-induced response (cell
cycle), nucleocytoplasmic transport of CDK/cyclins (cell cycle),
and DNA-damage-induced apoptosis were the most down-
regulated (data not shown).
Next, we analyzed direct interaction between the 61 differen-
tially expressed proteins. STAT1 directly interacted with
HSP90AA1, SERPINA3, and APOE, whereas HMGA1 interact-
ed with CD44. We then analyzed the transcription factors
regulating 61 differentially expressed proteins. The most promi-
nent regulatory proteins were c-MYC, SP1, and P53, interacting
with 21, 20, and 11 differentially expressed proteins, respectively.
Proteins directly activated by c-MYC included HSPE1,
HSP90AA1, LDHA, CDK2, HMGA1, EIF2S1, and YBX1.
Finally, we used the analyze network (AN) algorithm to reveal the
most relevant networks associated with the 61 differentially
expressed proteins. The networks were prioritized based on the
number of fragments of the canonical pathways in the network. As
a result, the top-scored AN network brought 11 proteins together:
up-regulated proteins were MYST4, HIST1H2BI, PPIB, AR-
L6IP5, CPNE1, PFN1, and DJ1; downregulated proteins were
YBX1, NACA, PRKDC, and CDK2.
To identify the potential proteomic markers, our first objective
was to focus on the up-regulated proteins that are categorized in
the biological processes related to melanoma progression or
metastasis (Table 3). These categories include cell structure and
motility, cell adhesion, cell defense, cell cycle, cell proliferation and
differentiation, apoptosis, metabolic process, and melanosome-
related. Interestingly, all of the listed proteins have been previously
implicated as cancer-related, and some have been suggested to be
related to metastasis, including pyruvate kinase isozymes M1/M2
(PKM2), glucose transporter isoform 1 (GLUT1), macrophage
migration inhibitory factor (MIF), peroxiredoxin-2 (PRDX2), L-
lactate dehydrogenase A chain (LDHA), and heat shock protein
HSP 90 alpha 2 (HSP90AA2). Furthermore, GLUT1,
HSP90AA2, prohibitin-2 (PHB2), peptidyl-prolyl cis-trans isom-
erase B precursor (PPIB), and L-lactate dehydrogenase A chain
(LDHA) have been identified in the melanosome. In Figure 3 we
provide representative MS tracings of XIC for specific peptides in
PKM2 and HSP90AA2. Figure 4 shows representative plots of
protein intensities of the four most significant proteins are shown:
PKM2 (q value=0.003), GLUT1 (q=0.007), HSP90AA2
(q=0.008) and L-lactate dehydrogenase B chain (LDHB,
q=0.008) in individual samples of primary and metastatic
melanomas.
IHC Analysis of Proteins
We examined several key proteins that were significantly
upregulated in metastasis compared to primary melanoma. IHC
Figure 1. Location and functional distribution of proteins isolated and identified from melanoma FFPE tissue. Proteins are categorized
by A) cellular origin and, B) biological process, based on the Gene Ontology database.
doi:10.1371/journal.pone.0004430.g001
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Accession number Gene Symbol Annotation # of peptides sequenced q-value
Summary of Upregulated Proteins*
P62701 RPS4X 40S ribosomal protein S4, X isoform 2 0.003
P14786 PKM2 Pyruvate kinase isozymes M1/M2 20 0.003
Q8TBK5 RPL6 60S ribosomal protein L6 2 0.005
Q02878 GAPDHS Glyceraldehyde-3-phosphate dehydrogenase, testis-specific 3 0.006
Q59GX2 GLUT1 Solute carrier family 2, facilitated glucose transporter member 1 2 0.007
Q14568 HSP90AA2 Heat shock protein HSP 90-alpha 2 17 0.008
P07195 LDHB L-lactate dehydrogenase B chain 12 0.008
Q5RKT7 RPS27A 40S ribosomal protein S27a 4 0.011
P00354 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 24 0.012
Q6FHV0 MIF Macrophage migration inhibitory factor 4 0.012
Q9BVK5 PPIB Peptidyl-prolyl cis-trans isomerase B precursor 6 0.012
Q3B872 HIST1H2BI Histone H2B type 1-C/E/F/G/I 10 0.013
Q3KQT6 RPS2 40S ribosomal protein S2 3 0.014
Q5J7W1 PGK1 Phosphoglycerate kinase 1 20 0.014
Q8WV32 TALDO1 Transaldolase 2 0.016
Q99497 DJ1 Protein DJ-1 8 0.016
Q9UBU5 PRDX5 Peroxiredoxin-5, mitochondrial precursor 4 0.016
Q76LA1 CSTB Cystatin-B 3 0.016
Q53X54 HSPE1 10 kDa heat shock protein, mitochondrial 3 0.019
Q96DW8 SERPINA3 Alpha-1-antichymotrypsin precursor 2 0.02
Q9NTZ7 CPNE1 Copine-1 2 0.021
Q53Y44 PFN1 Profilin-1 6 0.021
Q8WU81 MYST4 Histone acetyltransferase MYST4 2 0.021
P05141 SLC25A5 ADP/ATP translocase 2 7 0.021
Q86WV2 COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial precursor 2 0.023
P12236 SLC25A6 ADP/ATP translocase 3 5 0.023
P42224 STAT1 Signal transducer and activator of transcription 1-alpha/beta 4 0.026
P31945 PRDX2 Peroxiredoxin-2 8 0.028
P07900 HSP90AA1 heat shock protein 90 kDa alpha 4 0.029
Q53ES3 ARL6IP5 PRA1 family protein 3 2 0.03
P14866 HNRPL Heterogeneous nuclear ribonucleoprotein L 2 0.034
P13797 PLS3 Plastin-3 3 0.036
Q99623 PHB2 Prohibitin-2 6 0.04
Q9UDE9 LDHA L-lactate dehydrogenase A chain 17 0.041
P16402 HIST1H1D Histone H1.3 6 0.041
Q9H4B7 TUBB1 tubulin, beta 1 6 0.043
P02792 FTL Ferritin light chain 5 0.047
P32077 PRDX6 Peroxiredoxin-6 4 0.047
Summary of Downregulated Proteins*:
P33121 ACSL1 Long-chain-fatty-acid–CoA ligase 1 2 0.003
Q5T0R7 CAP1 Adenylyl cyclase-associated protein 1 4 0.003
P36957 DLST Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate
dehydrogenase complex, mitochondrial precursor
2 0.003
Q53FQ6 CAPZA1 F-actin capping protein subunit alpha-1 2 0.004
P31930 UQCRC1 Ubiquinol-cytochrome-c reductase complex core protein 1, mitochondrial
precursor
3 0.005
Q59EQ5 CSRP1 Cysteine and glycine-rich protein 1 2 0.006
P07585 DCN Decorin precursor 2 0.007
P24941 CDK2 Cell division protein kinase 2 4 0.009
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analysis. The results are ordered by 2log10 of the p-value of the hypergeometric distribution. A) GeneGo canonical pathway maps, and B) GeneGo
cellular process.
doi:10.1371/journal.pone.0004430.g002
Table 2. Cont.
Accession number Gene Symbol Annotation # of peptides sequenced q-value
Q6LBZ1 APOE Apolipoprotein E precursor 4 0.009
Q96QM7 LUM Lumican precursor 6 0.009
Q9Y4L1 HYOU1 150 kDa oxygen-regulated protein precursor 4 0.011
Q504S5 CKAP4 Cytoskeleton-associated protein 4 3 0.012
P62241 RPS8 40S ribosomal protein S8 3 0.016
P78528 PRKDC DNA-dependent protein kinase catalytic subunit 2 0.016
P05198 EIF2S1 Eukaryotic translation initiation factor 2 subunit 1 2 0.017
P15586 GNS N-acetylglucosamine-6-sulfatase precursor 2 0.021
P41219 PRPH Peripherin-2 3 0.021
Q9UKB0 HMGA1 High mobility group protein HMG-I/HMG-Y 2 0.022
Q3KQV4 NACA Nascent polypeptide-associated complex subunit alpha 2 0.024
Q4V324 GAGE7 G antigen 7 3 0.026
P67809 YBX1 Nuclease sensitive element-binding protein 1 4 0.031
P13667 PDIA4 Protein disulfide-isomerase A4 precursor 4 0.034
Q16208 CD44 CD44 antigen precursor 2 0.042
*Proteins with significant changes greater than 20%.
doi:10.1371/journal.pone.0004430.t002
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In Figure 5 we show representative examples of IHC staining of
PKM2, HSP90 alpha, MIF, and STAT1 in both primary and
metastatic melanomas. These studies confirmed the MS analysis of
proteins in melanomas.
Discussion
Quantitative proteome analysis by MS has become a useful tool
for understanding biological functions. While FFPE tissues offer
great opportunity for retrospective proteomic analysis, isolating
proteins from FFPE tissues suitable for MS analysis has been a
challenge. Quality control and uniformity of preparation across, or
even within, institutions remain problematic [27]. The reproduc-
ibility of results requires further validation on a large set of
specimens.
In the present study, the global protein expression profile in
FFPE tissue lysates of melanoma metastases was compared with
that of primary tumors. Throughout this study, we have addressed
several questions regarding FFPE melanoma tissues: (1) Is this
methodology useful for profiling the protein expression of archival
tissue? (2) How many proteins can be identified from small
quantities of FFPE melanoma tissue using Liquid TissueH reagents
and high resolution LC-ESI/MS/MS? (3) Do specific identified
proteins discriminate between metastatic and primary tissue? (4)
Can known melanoma-related biomarkers be identified? (5) Are
any known metastasis-related markers identified? (6) Can the
identified protein be validated by other methods?
We have demonstrated that proteins can be extracted from
microdissected FFPE tissues and utilized for MS analysis. Using
LC/MS/MS analysis, over 1500 proteins can be identified in a
small amount of cells (the equivalent of approximately 5,000 cells
per injection). Moreover, identified proteins appear to cover a
wide variety of biological functions and appear in diverse cellular
compartments. The proteomic profiling of FFPE tissue demon-
strated the detection of the major known melanogenesis pathway
proteins that are known to be expressed in melanomas. Over 70%
of previously known common melanosomal proteins can be
identified, including four of the six well known melanoma specific
markers. MART1 and TRP2 were not identified, which may
either be due to their low abundance or interference from melanin
[28,29]. Melanin has been shown to bind to proteins, causing
difficulties in protein solubility and binding affinity to chromatog-
raphy columns, which impairs protein characterization using LC/
MS analysis [30,31]. It has been demonstrated that MART1 can
be identified only if melanin is removed before 2D-LC/MS [29].
Lack of detection of some proteins may be due to the level of
protein in the tissues. Of the 120 differentially expressed proteins
identified with multiple peptides, 61 showed differences exceeding
20%. Many of these proteins have been reported to be associated
with characteristic steps of metastasis including motility, adhesion,
migration and tumor progression including cellular defense,
apoptosis, and proliferation.
Several of the up-regulated proteins (Table 3) identified in this
study have been described previously and implicated as cancer-
related. Some proteins are implicated as metastasis-related
proteins (e.g. LDH, HSP90, GLUT1, MIF, DJ1, PKM2 and
PHB2). HSP90 and GLUT1 have been previously described in
melanoma metastasis tissues as up-regulated [32,33]. LDH protein
levels have been described in serum from melanoma patients [34].
The expression of pyruvate kinase, HSP90 alpha, MIF, and
STAT1 in primary and metastatic melanomas could be demon-
strated by IHC staining. Upregulated expression levels of these
proteins in melanoma metastasis compared to primary melanomas
were demonstrated, confirming MS analysis.
In addition, LDHA, HSP90, GLUT1, MIF, DJ1, PKM2 PHB2,
PGK1 and PPIB are secreted from cancer cells and can be
detected in the blood, offering great potential as biomarkers of
tumor progression. It may be interesting to investigate whether
these proteins are involved in melanoma progression. Many of
these proteins are poorly-documented, and their role in metastasis
requires further investigation (e.g. MYST4, PLS3, and TUBB1).
We were able to identify several proteins implicated in melanoma
progression and metastasis; their biological functions and dereg-
ulations in tumorigenesis and metastasis are further discussed
below.
Plastins are actin-binding proteins that have three cell-type
specific isoforms: T-plastin, L-plastin and I-plastin. L-plastin is
expressed in hemapoietic cells, while T-plastin is in cells of solid
tissue, including fibroblasts, epithelial cells, and melanocytes.
Upregulation of L-plastin has been well documented in many
types of cancer [35] and has been implicated in metastasis [36].
However, the role of T-plastin in tumor progression is not known
and overexpression of T-plastin in cultured fibroblasts showed
increased mobility and altered cellular architecture. Although
PLS3 (T-plastin) has not been reported to be specifically present in
the melanosome organelle, it has been shown to be expressed in
melanocytes [37].
HSP90 has been a potential target for cancer therapy in the last
decade, and a HSP90 inhibitor, 17-allylamino-17 demethoxygel-
danamycin (17-AAG), is currently in clinical trials [38]. HSP90 is
involved in maintaining the conformation, stability, activity, and
cellular localization of several key oncogenic client proteins,
including ERBB2, C-RAF, CDK4, AKT/PKB mutated P53,
Table 3. Selected Up-regulated Proteins in Melanoma Metastasis.
Category Gene Symbol
Cell Structure and Motility, Cell Adhesion TUBB1, PLS3
Cell Cycle MYST4, PHB2, TUBB1
Cell proliferation and differentiation DJ1, MYST4, PHB2
Cell Defense MIF, PPIB, DJ1, PRDX5, PRDX2, PRDX6, HSP90AA2
Carbohydrate metabolic process PKM2, GLUT1,LDHB, LDHA, PGK1
Protein metabolic process HSP90AA1, HSP90AA2, HSPE1, MYST4, PPIB
Nucleic acid metabolic process DJ1, MYST4, PHB2, STAT1
Melanosome-Associated PKM2, GLUT1, HSP90AA1, PPIB, PHB2, LDHA, PLS3
doi:10.1371/journal.pone.0004430.t003
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hTERT, and steroid hormone receptors [39]. Inhibition of
HSP90 simultaneously targets multiple oncogenes and pathways,
as well as characteristic traits of malignancy. HSP90a, an isoform
of HSP90, is stress-inducible and overexpressed in many cancer
cells [40]. Furthermore, HSP90a has been shown to be related to
invasiveness and found to be secreted [40]. HSP90 mRNA levels
are up-regulated in primary and metastatic melanoma when
compared to melanocytic nevi [32]. Our analysis showed
significantly higher levels of HSP90 protein in metastatic than in
primary melanomas.
DJ1 protein was initially discovered as a putative oncogene that
promotes cell survival by negatively regulating tumor suppressor
PTEN [41]. DJ1 has also been implicated in cell protection against
stresses including chemotherapy and oxidative stresses, [42].
Overexpression of DJ1 has been shown to be associated with
tumorigenesis. Interestingly, DJ1 has been detected in serum from
uveal malignant melanoma patients [43].
MYST4, a member of the MYST histone acetyltransferase family,
may be involved in both upregulation and downregulation of
tumorigenesis. MYST4 reportedly fuses to the transcription co-
activators CBP, p300, and TIF2 in acute myeloid leukemia. MYST4
was shown to be required for RUNX2-dependent transcriptional
activation, and to interact with P53 in cancer [44,45]. There is little
information about the expression profile of MYST4 in cancer.
Further investigation is needed to determine whether MYST4 is
associated with brain metastasis, since MYST4 has been implicated
in neural development and maintenance of neural stem cells, and in
this study we found MYST4 expression is higher in brain melanoma
metastases when compared to primary melanoma.
Proteins of the prohibitin family (PHB1 and PHB2) are localized
in many cellular compartments (e.g. mitochondria, nucleus, and
cell-surface) and may have diverse functions in different locations.
PHB appears to function as a chaperone in the stabilization of
mitochondrial proteins [46], yet the functions of nuclear PHB are
still controversial. PHB has been proposed to play a role as a
potential tumor suppressor, but higher levels of PHB protein have
been reported in a variety of cancers [47]. Prohibitin was
demonstrated to play an unexpected role in the activation of the
Ras-Raf signaling pathway and in modulating epithelial cell
adhesion and migration, indicating that PHB may play a role in
metastasis formation [47].
Several of the most significant proteins identified that increased
in metastasis were those involved in the aerobic glycolysis pathway
in cancer cells (Warburg effect). Particular upregulated proteins
were GLUT1, PKM1/M2, PGK1, and LDHA/B. Most of these
proteins have been shown to be upregulated in cancer, including
melanomas. Interestingly, in our analysis these proteins of the
glycolysis pathway were quite significantly elevated in metastatic
tissues. LDHA and LDHB are subunits of lactate dehydrogenase
(LDH) and associate to generate five tetrameric forms of LDH
isoenzymes. LDHA is involved in metabolic activities, particularly
the redox reaction at the end of glycolysis. An enhanced level of
LDHA is observed in cancer cells and a higher level of LDHA is
associated with proliferation [48]. Elevated serum levels of LDH
indicate progression of AJCC stage IV melanoma; LDH is a
biomarker for AJCC staging of melanomas [49]. Our results
support the finding that upregulation of LDH in cells is related to
aggressive metastatic melanoma tumors.
GLUT1 may be responsible for constitutive or basal glucose
uptake. Overexpression of GLUT1 is associated with increased
glucose metabolism and has been correlated with progression of
several types of cancer [50]. Studies have shown that GLUT1 is
modulated by hypoxia-responsive elements and upregulated by
overexpression of HIF-1 [51]. GLUT1 protein is expressed in
most melanoma metastases with a broad range of expression levels
as shown by Western immunoblot analysis [33]. Our results
confirm these findings.
PKM2 is an M2 type of pyruvate kinase (PK) which plays a
critical role in aerobic glycolysis regulation in tumorigenesis.
During oncogenesis, the PK isoform M1 is converted to PKM2
and is present as a less active dimer form. PKM2 is up-regulated in
tumor cells, and is under control of Ras and transcription factors
HIF-1, SP1, and SP2. Interestingly, tumor M2-PK is expressed at
higher levels in metastases than in primary tumors, and the level of
PKM2 in plasma of various cancer types is correlated with tumor
size and stage [52]. Recent studies have shown that PKM2 isoform
is highly necessary for aerobic glycolysis, which provides a selective
growth advantage for tumor cells [53].
PGK1 (phosphoglycerate kinase), which is involved in the
glycolytic pathway, is regulated by HIF-1a and is enhanced in
states of hypoxia due to increased demand for glycolysis. PGK1 also
affects DNA replication and repair in the nucleus. Extracellular
secretion of PGK1 by tumor cells increases angiostatin activity,
causing inhibition of angiogenesis. In several types of cancer, PGK1
has been shown to be up-regulated [54]. In pancreatic cancers,
PGK1 is secreted into the bloodstream, and studies have shown
increased levels of serum PGK1. Therefore, this protein shows
promise as a potential serum marker for cancer [54].
In this report, Liquid TissueH reagents effectively solubilized
proteins and peptides from microdissected formalin-fixed melano-
ma tissues and enabled proteomics analysis by ESI-LC MS/MS.
Global protein profiling using label-free protein quantitative
analysis revealed potential metastasis-related proteins that are
differentially expressed between metastatic and primary melano-
ma. Up-regulation of some of these proteins has been previously
implicated in tumor progression by other methodologies and is in
accordance with our findings. Hence, the method described here is
extremely useful for proteomics studies in a high-throughput
setting. Moreover, in the search for potential biomarker,
candidates can be confirmed in a larger set of samples to validate
the findings. The advantage of this approach is that it allows
analysis of retrospective tumor tissue specimens with known
disease outcomes. This provides a unique strategy to develop new
molecular prognostic biomarkers of melanoma.
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Figure 3. MS tracings of representative specific peptides. X-axis: retention time. Y-axis: peak intensity. A) Extracted ion chromatogram (XIC)
for peptide GDYPLEAVR from pyruvate kinase isozymes M1/M2 of representative samples. Primary melanoma samples A.1 and A.2 are duplicate
samples. Metastatic melanoma samples B.1 and B.2 are duplicates. Peak intensities were calculated by smoothing (as indicated by the green and red
trace lines) and integrating the AUC of smoothed peaks for all samples within the same one-minute window (RT from 45.5 min to 46.5 min as
indicated by the red trace line). B) Extracted ion chromatogram (XIC) for peptide ALLFVPR from heat shock protein HSP90AA2 of representative
samples. Primary melanoma samples A.1 and A.2, and samples B.1 and B.2, are duplicate samples, respectively. Metastatic melanoma samples B.1 and
B.2 are duplicates. RT from 59.7 min to 60.7 min as indicated by the red trace line.
doi:10.1371/journal.pone.0004430.g003
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PLoS ONE | www.plosone.org 9 February 2009 | Volume 4 | Issue 2 | e4430Figure 4. Representative plots of protein intensities in the individual samples of primary and metastatic melanoma. The individual
protein intensities for A) PKM2, B) GLUT1, C) HSP90AA2, and D) LDHB Are plotted on a log2 scale. The horizontal line is the group mean, and
duplicate intensities of individual samples are joined by a vertical line.
doi:10.1371/journal.pone.0004430.g004
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